Search Page

1

Cite

Share

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Rabe KF. Rabe KF. Br J Pharmacol. 2011 May;163(1):53-67. doi: 10.1111/j.1476-5381.2011.01218.x. Br J Pharmacol. 2011. PMID: 21232047 Free PMC article. Review.

Cite

Share

2

Cite

Share

Efficacy of roflumilast in the COPD frequent exacerbator phenotype.

Wedzicha JA, Rabe KF, Martinez FJ, Bredenbröker D, Brose M, Goehring UM, Calverley PMA. Wedzicha JA, et al. Among authors: rabe kf. Chest. 2013 May;143(5):1302-1311. doi: 10.1378/chest.12-1489. Chest. 2013. PMID: 23117188 Clinical Trial.

Cite

Share

3

Cite

Share

Roflumilast for the treatment of chronic obstructive pulmonary disease.

Rabe KF. Rabe KF. Expert Rev Respir Med. 2010 Oct;4(5):543-55. doi: 10.1586/ers.10.56. Expert Rev Respir Med. 2010. PMID: 20649375 Review.

Cite

Share

4

Cite

Share

Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.

Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Rabe KF, et al. Lancet. 2006 Aug 26;368(9537):744-53. doi: 10.1016/S0140-6736(06)69284-2. Lancet. 2006. PMID: 16935685 Clinical Trial.

Cite

Share

5

Cite

Share

Markers of exacerbation severity in chronic obstructive pulmonary disease.

Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Franciosi LG, et al. Among authors: rabe kf. Respir Res. 2006 May 10;7(1):74. doi: 10.1186/1465-9921-7-74. Respir Res. 2006. PMID: 16686949 Free PMC article.

Cite

Share

6

Cite

Share

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.

Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD. Rabe KF, et al. Lancet. 2005 Aug 13-19;366(9485):563-71. doi: 10.1016/S0140-6736(05)67100-0. Lancet. 2005. PMID: 16099292 Clinical Trial.

Cite

Share

7

Cite

Share

Burden and clinical features of chronic obstructive pulmonary disease (COPD).

Pauwels RA, Rabe KF. Pauwels RA, et al. Among authors: rabe kf. Lancet. 2004 Aug 14-20;364(9434):613-20. doi: 10.1016/S0140-6736(04)16855-4. Lancet. 2004. PMID: 15313363 Review.

Cite

Share

8

Cite

Share

Markers of disease severity in chronic obstructive pulmonary disease.

Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Franciosi LG, et al. Among authors: rabe kf. Pulm Pharmacol Ther. 2006;19(3):189-99. doi: 10.1016/j.pupt.2005.05.001. Epub 2005 Jul 12. Pulm Pharmacol Ther. 2006. PMID: 16019244

Cite

Share

9

Cite

Share

Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.

Grootendorst DC, Rabe KF. Grootendorst DC, et al. Among authors: rabe kf. Curr Opin Allergy Clin Immunol. 2002 Feb;2(1):61-7. doi: 10.1097/00130832-200202000-00010. Curr Opin Allergy Clin Immunol. 2002. PMID: 11964752 Review.

Cite

Share

10

Cite

Share

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.

Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbröker D, Bethke TD, Hiemstra PS, Rabe KF. Grootendorst DC, et al. Among authors: rabe kf. Thorax. 2007 Dec;62(12):1081-7. doi: 10.1136/thx.2006.075937. Epub 2007 Jun 15. Thorax. 2007. PMID: 17573446 Free PMC article. Clinical Trial.

Cite

Share